RedShift BioAnalytics

RedShiftBio's Aurora TX delivers automated, precise structural analysis with thermal ramping for insights into biomolecule stability and function.

The HaLCon Protein Analyzer’s reagent pack and module analyze up to 1,000 samples, enabling high-quality titer measurements quickly and efficiently.

Measure protein titer in real time with HaLCon. This automated analyzer delivers HPLC-level accuracy in minutes to streamline bioprocess decisions.

RedShiftBio offers Aurora TX for MMS structural characterization and HaLCon for real-time, HPLC-level titer measurement.

Aurora TX by RedShiftBio is for protein and RNA analysis with MMS. RedShiftBio offers a free StructIR lab project through 3/31/26.

RedShiftBio showcased MMS at WCBP 2019, advancing IR-based protein analysis and demonstrating amyloid aggregation characterization with Pressure Biosciences.

MMS detects structural differences below 2% to predict biosimilar stability.

RedShift describes its work environment as fast-paced, dynamic, and intellectually challenging, with like-minded colleagues.

Dennis Merrill, COO at RedShiftBio, drives innovation with 20+ years leading spectroscopic tech for industrial, medical, and lab markets.

Eugene is responsible for technology innovation and data analytics at RedShiftBio.

RedShiftBio's leadership team provides next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules.

Sean Veale has 20+ year experience creating software for scientific applications.

RedShiftBio is redefining structural biomolecule assessment and delivering novel analytical tools to the R&D, life science and biopharmaceutical markets.

RedShiftBio offers protein and RNA characterization and secondary structure analysis.

RedShiftBio offers automated, high-sensitivity biomolecule analysis for drug development, including protein and RNA structure, stability, and titer analysis.

RedShiftBio's privacy policy covers information collection, use, and third-party processing.

RedShiftBio introduces **Aurora TX**, a new instrument leveraging **Microfluidic Modulation Spectroscopy (MMS)** to enhance IR spectroscopy for measuring protein structure, stability, aggregation, and binding. The device enables thermal ramping experiments to analyze stability and aggregation in protein secondary structures or RNA/DNA base pairing. Aurora TX improves sensitivity, dynamic range, and accuracy for structural biology research.

Jan 2026redshiftbio.comNews article

RedShiftBio’s CEO, Tom O’Lenic, participates in the **44th Annual J.P. Morgan Healthcare Conference**, engaging with customers, partners, and industry leaders. The event serves as a platform for networking and strategic discussions in the biotech sector. RedShiftBio focuses on advancing gene editing and cell therapy solutions.

Jan 2026redshiftbio.comNews article

RedShiftBio introduces the **2025 Structure Lab Grant Program** to support researchers using its **Aurora TX** instrument. The device leverages **Microfluidic Modulation Spectroscopy (MMS)** to enhance IR spectroscopy sensitivity, dynamic range, and accuracy for protein and nucleic acid analysis. It enables thermal ramping experiments to study stability, aggregation, and secondary structure dynamics in biomolecules.

Feb 2025redshiftbio.comNews article

RedShiftBio introduces **Aurora TX**, a system using **Microfluidic Modulation Spectroscopy (MMS)** to analyze RNA, proteins, and peptides. The device automates structural and stability characterization, including **thermal ramping**, for deeper biomolecular insights. It delivers high-sensitivity measurements with minimal user input.

May 2024redshiftbio.comNews article